247 related articles for article (PubMed ID: 29294323)
21. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
22. Novel Galactosylated Poly(ethylene glycol)-Cholesterol for Liposomes as a Drug Carrier for Hepatocyte-Targeting.
Zhang H; Xiao Y; Cui S; Zhou Y; Zeng K; Yan M; Zhao C
J Nanosci Nanotechnol; 2015 Jun; 15(6):4058-69. PubMed ID: 26369013
[TBL] [Abstract][Full Text] [Related]
23. In Vitro and In Vivo Evaluation of SP94 Modified Liposomes Loaded with N-14NCTDA, a Norcantharimide Derivative for Hepatocellular Carcinoma-Targeting.
Jiang Y; Liu X; Tan X; Hou Y; Sun W; Gou J; Yin T; He H; Zhang Y; Tang X
AAPS PharmSciTech; 2020 Oct; 21(7):277. PubMed ID: 33033942
[TBL] [Abstract][Full Text] [Related]
24. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
25. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
26. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
27. Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma.
Abdelmoneem MA; Mahmoud M; Zaky A; Helmy MW; Sallam M; Fang JY; Elkhodairy KA; Elzoghby AO
Nanomedicine (Lond); 2018 Oct; 13(19):2377-2395. PubMed ID: 30346255
[TBL] [Abstract][Full Text] [Related]
28. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
[TBL] [Abstract][Full Text] [Related]
29. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.
Zhang W; Peng F; Zhou T; Huang Y; Zhang L; Ye P; Lu M; Yang G; Gai Y; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2015; 10():4825-36. PubMed ID: 26251599
[TBL] [Abstract][Full Text] [Related]
30. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting: synthesis, characterization, and proof of concept of hepatospecific delivery.
Pathak PO; Nagarsenker MS; Barhate CR; Padhye SG; Dhawan VV; Bhattacharyya D; Viswanathan CL; Steiniger F; Fahr A
Carbohydr Res; 2015 May; 408():33-43. PubMed ID: 25841057
[TBL] [Abstract][Full Text] [Related]
31. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
He Y; Zhang L; Song C
Int J Nanomedicine; 2010 Sep; 5():697-705. PubMed ID: 20957221
[TBL] [Abstract][Full Text] [Related]
32. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
Gu Z; Chang M; Fan Y; Shi Y; Lin G
Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.
Alanazi SA; Harisa GI; Badran MM; Alanazi FK; Elzayat E; Alomrani AH; Al Meanazel OT; Al Meanazel AT
Bioengineered; 2021 Dec; 12(1):914-926. PubMed ID: 33678142
[TBL] [Abstract][Full Text] [Related]
34. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
35. Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system.
Zhang X; Zhang X; Yu P; Han Y; Li Y; Li C
J Pharm Sci; 2013 Jan; 102(1):145-53. PubMed ID: 23132353
[TBL] [Abstract][Full Text] [Related]
36. Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma.
Bansal D; Yadav K; Pandey V; Ganeshpurkar A; Agnihotri A; Dubey N
Drug Deliv; 2016; 23(1):140-6. PubMed ID: 24786484
[TBL] [Abstract][Full Text] [Related]
37. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
[TBL] [Abstract][Full Text] [Related]
38. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation.
De Luca MA; Lai F; Corrias F; Caboni P; Bimpisidis Z; Maccioni E; Fadda AM; Di Chiara G
Int J Pharm; 2015 Feb; 479(1):129-37. PubMed ID: 25560308
[TBL] [Abstract][Full Text] [Related]
39. Biotin-directed assembly of targeted modular lipoplexes and their transfection of human hepatoma cells in vitro.
Singh A; Ariatti M; Singh M; Hawtrey A; Naidoo R
Drug Deliv; 2010 Aug; 17(6):426-33. PubMed ID: 20469969
[TBL] [Abstract][Full Text] [Related]
40. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
